版本:
中国

BRIEF-Coherus Biosciences says FDA acceptance of 351(K) biologics license application

Oct 6 Coherus Biosciences

* Announces FDA Acceptance Of 351(K) Biologics License Application to U.S. Food And Drug Administration for CHS-1701 (pegfilgrastim biosimilar candidate)

* Biosimilar User Fee Act (BSUFA) action date is June 9, 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐